'Lipoproteins, glycoxidation and diabetic angiopathy'

被引:68
|
作者
Jenkins, AJ
Best, JD
Klein, RL
Lyons, TJ
机构
[1] Univ Melbourne, Dept Med, St Vincents Hosp, Fitzroy, Vic, Australia
[2] Med Univ S Carolina, Div Endocrinol Diabet Med Genet, Charleston, SC USA
[3] Univ Oklahoma, Hlth Sci Ctr, Endocrinol Metab & Hypertens Sect, Oklahoma City, OK 73104 USA
关键词
lipoproteins; advanced glycation end-products; oxidation; diabetes; vascular disease;
D O I
10.1002/dmrr.491
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The chronic vascular complications of diabetes (nephropathy, retinopathy and accelerated atherosclerosis) are a major cause of morbidity and premature mortality. In spite of the more widespread availability of intensive diabetes management, approximately one in three people with diabetes develop aggressive complications and over 70% die of atherosclerosis-related diseases. Genetic and acquired factors are likely to be contributory. Potential mediators of vascular damage may include the interrelated processes of lipoprotein abnormalities, glycation, oxidation and endothelial dysfunction. Lipoprotein abnormalities encompass alterations in lipid concentrations, lipoprotein composition and subclass distribution and lipoprotein-related enzymes. Nonenzymatic glycation and oxidative damage to lipoproteins, other proteins and to vascular structures may also be deleterious. As atherosclerosis is a chronic condition commencing in youth, and because clinical events may be silent in diabetes, surrogate measures of vascular disease are important for early identification of diabetic patients with or at high risk of vascular damage, and for monitoring efficacy of interventions. The increasing array of biochemical assays for markers and mediators of vascular damage, noninvasive measures of vascular health, and therapeutic options should enable a reduction in the excessive personal and economic burden of vascular disease in type 1 and type 2 diabetes. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:349 / 368
页数:20
相关论文
共 50 条
  • [21] A PATHOLOGISTS VIEW OF DIABETIC ANGIOPATHY
    GEILER, G
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1967, 92 (36) : 1640 - &
  • [22] DIABETIC MICRO-ANGIOPATHY
    STANDL, E
    MEDIZINISCHE WELT, 1983, 34 (05): : 149 - 152
  • [23] DIABETIC ANGIOPATHY - DIAGNOSIS AND PREVENTION
    MAZHUL, LM
    BELOZEROVA, LR
    GAVRILOV, VB
    GATSKO, GG
    KLINICHESKAYA MEDITSINA, 1991, 69 (11): : 76 - 79
  • [24] Pathophysiological mechanisms of diabetic angiopathy
    Hammes, HP
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2003, 17 (02) : 16 - 19
  • [25] HEMOSTASIS AND CIRCULATION IN DIABETIC ANGIOPATHY
    PETROVA, TR
    VILCHISKAYA, MN
    SOVETSKAYA MEDITSINA, 1984, (04): : 98 - 101
  • [26] Molecular mechanism of diabetic angiopathy
    Watanabe, T
    Yonekura, H
    Yamamoto, Y
    Sakurai, S
    Yamamoto, H
    SEIKAGAKU, 2003, 75 (10): : 1361 - 1370
  • [27] ENDOTHELIAL DYSFUNCTION AND DIABETIC ANGIOPATHY
    WASCHER, TC
    TOPLAK, H
    DIABETOLOGIA, 1994, 37 (11) : 1167 - 1168
  • [28] DIABETIC MICRO-ANGIOPATHY
    不详
    LANCET, 1954, 2 (SEP11): : 536 - 537
  • [29] HEPARIN IN THERAPY OF DIABETIC ANGIOPATHY
    EFIMOV, AS
    CHEBAN, AK
    BEZVERKH.TP
    BUGLAK, NI
    DANILOVA, AI
    DONISH, RM
    ZUBKOVA, ST
    KARABUN, PM
    LAPKO, LI
    LIMANSKA.GF
    MALINKOV.VD
    SVYATELI.GV
    SKROBONS.NA
    TERAPEVTICHESKII ARKHIV, 1974, 46 (10) : 78 - 84
  • [30] HEMORHEOLOGICAL PARAMETERS IN DIABETIC ANGIOPATHY
    SPITZER, S
    KIESEWETTER, H
    JUNG, F
    FRANK, M
    WELLBROCK, U
    BERTRAM, B
    SCHWAB, J
    SITZMANN, F
    VONBLOHN, G
    WENZEL, E
    WEINGES, KF
    SCHIEFFER, H
    MEDIZINISCHE WELT, 1992, 43 (03): : 238 - 242